Dendritic Cell Vaccines: Personalized Cancer Immunotherapy
Consistent with our vision, we strive to offer individualized care that aligns with each patient's unique needs. To this end, we offer a technique at the cutting edge of oncology: dendritic cell vaccines. This personalized treatment uses your own immune cells to fight cancer, breaking new ground in the world of targeted therapies.
The Key Role of Dendritic Cells
Dendritic cells are key components of the immune system. Their main role is to act as messengers between innate and adaptive immune cells. In short, they "present" antigens to T cells, triggering a targeted immune response against pathogens or tumor cells.
The Dendritic Cell Vaccine Process
Sampling and isolation
Dendritic cells are harvested directly from your own blood, guaranteeing perfect compatibility and minimizing the risk of adverse reactions.
Laboratory activation
The isolated cells are then exposed to antigens specific to the cancer cells you carry. This enables precise, targeted activation of the dendritic cells.
Reinjection into the Patient
Activated dendritic cells are injected back into your body. They then go to the lymph nodes and incite a powerful immune response against the cancer cells.
Monitoring & Evaluation
A series of checks and assessments are carried out to measure the success of the therapy and adjust the treatment as required.
The Importance of Individualization
This treatment fits in perfectly with our philosophy of personalized health care. By using your own cells, we can create a treatment that is specifically tailored to your biological profile, greatly increasing the chances of success.
Benefits for Cancer
- Targeted and effective Because it uses antigens specific to your cancer cells, this vaccine is incredibly targeted.
- High tolerance Using your own cells reduces the risk of complications and side effects.
Conclusion: active immunotherapy Active immunotherapy such as DCV
Active immunotherapy, such as DCV, combines well with other treatments such as passive immunotherapy, like CIK-Cells therapy, which mobilizes the patient's immune system. Immunotherapies with CIKs and DCVs constitute an advanced combination therapy, as they work on very different principles, contributing to a broad and complex immune response against cancer.
Combination with ozonotherapy and the IV therapies we offer is also possible. There is also the possibility of combining with chemotherapy that patients may already be undergoing. This combined approach is not only compatible, but also advantageous;
Indeed, current research indicates that the combination of several therapeutic methods increases the success rate, offering a global strategy for the fight against cancer.
Clearly, given the complexity and importance of these therapies, they need to be discussed in consultation and strictly monitored.